Citadel Advisors
PBM icon

Citadel Advisors’s Psyence Biomedical PBM Stock Holding History

Citadel Advisors’s Portfolio PBM Stock Details PBM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.8K Buy
+11,693
New +$53.1K ﹤0.01% 13259
2025
Q2 		– Sell
-1,512
Closed -$45.2K – 15466
2025
Q1 		$45.2K Buy
1,512
+1,281
+555% +$81.5K ﹤0.01% 12408
2024
Q4 		$24.2K Buy
231
+186
+413% +$44.3K ﹤0.01% 13046
2024
Q3 		$16.9K Buy
+45
New +$60.9K ﹤0.01% 12908

Other funds holding PBM

PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SFFS
Stonehage Fleming Financial Services St. Helier, Jersey $2.93B AUM 16.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CJ
Caitlin John Brighton, Michigan $183M AUM 30.77% 1-Year Est. Return

Citadel Advisors's PBM Position: Q2 2026 in Review

Citadel Advisors opened a new position in Psyence Biomedical (PBM) in Q2 2026: 11,693 shares worth $35.8K. The stake represents ﹤0.01% of the portfolio and ranks #13259 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PBM as recently as Q1 2025.

Citadel Advisors first reported a position in PBM in Q3 2024 and has held it in 4 quarters since. The position peaked at $45.2K in Q1 2025. 9 funds tracked by Wall St. Rank hold PBM as of Q2 2026.

  • Citadel Advisors held 11,693 shares of Psyence Biomedical worth $35.8K as of Q2 2026.
  • Psyence Biomedical was a new Citadel Advisors position in Q2 2026.
  • Psyence Biomedical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13259 holding.
  • Citadel Advisors first reported a position in Psyence Biomedical in Q3 2024 and has held it in 4 quarters since.
  • Citadel Advisors's Psyence Biomedical position peaked at $45.2K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.